Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Present with a history of ED and signs and symptoms of BPH.~* Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.~Main Exclusion Criteria:~* Current treatment with nitrates.~* Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.~* PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate malignancy has not been ruled out to the satisfaction of a urologist~* Suffering from other urinary disease like cancer, or infection~* Serious cardiovascular disease~* History of significant renal insufficiency

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
- 5 mg Tadalafil (Type: EXPERIMENTAL): Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period
- 0.2 mg Tamsulosin (Type: OTHER): Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).